We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 60.50 | 60.00 | 61.00 | 60.50 | 60.50 | 60.50 | 14,770 | 07:44:37 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -2.77 | 8.07M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/1/2020 19:06 | One extreme to the other bob. Personally I believe they were on the cusp of a big deal with Texrad. It could still happen. In the meantime we hope that Bleepa is indeed the future of NHS communications. | ducatiman | |
08/1/2020 18:49 | Hi Ged, news always welcome even if it doesn’t move markets. We are in a waiting game again and it would be nice to know the strategy when/if the trials deliver the results expected. Is any work being done overseas or in other industries? Until we get news that drives the share price north of 2p it is hard to get too excited...and what about TexRAD it shouldn’t just be allowed to wither. Little clarity at present I’m afraid. | bobd29 | |
08/1/2020 14:05 | Such influence Bob! :)) The #Bleepa team are hard at work on plans for revolutionising healthcare in 2020 including our first pilot in @OldhamCO_NHS @NCAlliance_NHS | ged5 | |
07/1/2020 15:02 | Afternoon Ged, yes an update would be very welcome. Communication would go a long way towards keeping shareholders happy. | bobd29 | |
07/1/2020 09:23 | Good morning Bob. TexRAD seems to have been around a long time and I would like to see them get some value out of it. Others seem to be catching FDBK up. I'm not sure how tight past agreements have been. Stonechecker, Imaging Endpoints, GE Healthcare, what value are we getting? Perhaps the company could inform us. I wasn't here when AR made that statement so I don't recall. Good with words not so sure about the substance. He's now gone but we still haven't had an announcement since 19th November 2019. Let's hope the words of TO have more substance. If they do we should have an exciting few years. We could do with some sort of update about the trial, new agreements and CE mark. | ged5 | |
06/1/2020 18:28 | Thanks Ged, must have passed me by. Begs the question...if we are not going to focus on commercialising a clinical version, or further develop the programme beyond Lung, then why not sell TexRAD in order to fully focus on Bleepa? Many lths will disagree but if this toddler is ever to become a big fish (remember AR’s famous statement upon his appointment?) then income growth will be paramount. Just musing..... | bobd29 | |
06/1/2020 14:17 | Good afternoon Bob and thank you for getting us back on track. Just looking at the official announcements the most apt are this one from 17th October 2019 and the second one from the AGM statement. The Company continues to progress with its strategic review of TexRAD®, a longstanding part of the Feedback portfolio. The Company hopes to complete the strategic review by the end of the calendar year. "We have made some product modifications to TexRAD Research in response to customer feedback and are evaluating the impact of these on revenue. In the near term, we will continue to sell TexRAD within the research setting through third party distributors which provides a more cost-effective avenue for maintaining our sales efforts. As a result, we have reduced the resources associated with TexRAD. These changes also allow us to redirect our efforts and focus onto BleepaⓇ, which we believe holds the largest mid-term revenue opportunity for the Company. We will continue to assess opportunities for the TexRAD platform and will update the market as appropriate." | ged5 | |
06/1/2020 13:02 | Afternoon all, am I right in thinking we were promised a full TexRAD review a couple of months after the initial strategic review shortly following TO’s appointment? I seem to think it was due in Sept/Oct? Wonder what happened? Bleepa may have stolen the limelight but where is the TexRAD review? | bobd29 | |
06/1/2020 12:13 | Yes Ducatiman it was an interesting blend. I normally do salmon with a chili ginger sauce from the Hairy Bikers diet book but we had some chorizo left from our New Year's Eve starter - Scallops and chorizo. No Yump, too nice to drop! :)) I'll have to try that LR2. Meanwhile very little interest today. | ged5 | |
04/1/2020 12:17 | I often have mussels and chorizo but have never tried salmon and chorizo. Must find a recipe for it. | lr2 | |
04/1/2020 10:58 | Well I’ve heard of name dropping but is that food dropping ?! | yump | |
03/1/2020 21:21 | .98 Ged. Stock taken in at .953. Couldn’t sell diddely squat at .98 today. Salmon and chorizo! Interesting blend. Bon appetite. | ducatiman | |
03/1/2020 21:02 | I saw the .99 trade. Wasn't there just one? Anyway I found a link to the video that was in the header that works. I had to do something. We were having a quiet salmon and chorizo meal with a glass or two of Sauvignon Blanc when my son phoned to talk about his forthcoming wedding. No alarms this time. | ged5 | |
03/1/2020 19:50 | Couple of mates rates buys today I reckon. | ducatiman | |
03/1/2020 10:01 | Probably best to remove it. Am getting 'Your connection is not private' message followed by 'Attackers might be trying to steal your information from www.turing-gateway.c NET::ERR_CERT_DATE_I | lr2 | |
03/1/2020 09:37 | Thanks for that, LR2. It has relevance to me living in that area. It does annoy me though seeing others getting this commercial success. I just checked the link in the header to remind myself of what we read over a year ago. "Textural Analysis for the Prediction of Cerebrovascular Events" It didn't work for me saying my clock was misconfigured. If anyone else gets a warning message please let me know and I'll remove the link. Pity it showed how Textural Analysis detects warning signs in the brain. | ged5 | |
02/1/2020 17:55 | I'm not declaring that I'm uninformed but it was an interesting part to his answer. I haven't seen a CEO endorse another company's product before so that for me was quite something. I'm not sure that he was suggesting Bleepa was AI. You're quite right to point out that Bleepa is not AI. It was derived from Cadran which was PACS. TexRAD is the AI product and could/should have been used in many different areas by now although I understand it is best applied to lung applications. Hope your son is OK, Davydoo and Social Services are not involved! ;)) | ged5 | |
02/1/2020 17:10 | Davydoo, with a couple of 100 per centers thrown in :-) | ducatiman | |
02/1/2020 16:34 | I'd take that comment from GB, although interesting for the uninformed, with a pinch of salt as he lumped it in with an answer about AI, which I raised as a potentially useful and very wide-ranging aid to all sorts of diagnoses, if it were formed in a single source for consultants and GP's. Bleepa, however brilliant it turns out to be, or not, is not AI - its just a clever individual app. To some people, everything new is game-changing ;-) | yump | |
02/1/2020 15:52 | for 2020 i'll take 1% up per day | davydoo | |
02/1/2020 15:15 | Happy new year to you too Ged. I thought that Texrad would have made a breakthrough before now. CRUK early detection award, cost savings, more efficient, faster. Maybe it will make an impact soon. Good to read Bleepa being hailed as "game changing". | ducatiman | |
02/1/2020 12:51 | Item coming up shortly on BBC news 24, AI better at detecting breast cancer. Could be worth watching but we already know that don't we? | ducatiman | |
02/1/2020 12:12 | Took my son for an X Ray today, my wife who works in Veterinary medicine wanted to see the xray so i took a photo of the monitor Wouldn't it have been great to ask them to send it her Bleepa | davydoo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions